Stifel Nicolaus Lowers Cooper Companies (NASDAQ:COO) Price Target to $105.00

Cooper Companies (NASDAQ:COO) had its target price lowered by stock analysts at Stifel Nicolaus from $115.00 to $105.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 23.53% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a research note on Friday. Morgan Stanley lowered their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Citigroup lowered their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday. JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Wells Fargo & Company increased their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Price Performance

COO opened at $85.00 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The stock has a market capitalization of $16.96 billion, a P/E ratio of 43.59, a P/E/G ratio of 2.25 and a beta of 1.02. The company’s 50-day simple moving average is $92.38 and its two-hundred day simple moving average is $99.40. Cooper Companies has a 52-week low of $82.61 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. As a group, analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Institutional Investors Weigh In On Cooper Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Cooper Companies by 23.0% during the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after acquiring an additional 737,726 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Cooper Companies during the 4th quarter worth approximately $691,000. Highland Capital Management LLC purchased a new stake in Cooper Companies during the 4th quarter valued at approximately $4,004,000. Caprock Group LLC purchased a new stake in Cooper Companies during the 4th quarter valued at approximately $282,000. Finally, Franklin Resources Inc. grew its holdings in Cooper Companies by 194.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after buying an additional 32,260 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.